Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...

Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

With multiple respiratory viruses traveling throughout Wisconsin, the Department of Health Services (DHS) urges Wisconsinites ...

This fall saw an unusually high number of cases of “walking” or mycoplasma pneumonia, a mild pneumonia that typically causes ...